Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Shanghai Menon Animal Nutrition Technology
301156
5
Nanjing Railway New Technology
301016
US Stock MarketDetailed Quotes
HALO Halozyme Therapeutics
- 61.920
- -1.100-1.75%
Close Apr 3 16:00 ET
- 60.900
- -1.020-1.65%
Pre 07:34 ET
7.65BMarket Cap18.05P/E (TTM)
63.140High61.230Low1.88MVolume62.070Open63.020Pre Close116.94MTurnover1.54%Turnover Ratio18.05P/E (Static)123.53MShares66.00052wk High21.03P/B7.57BFloat Cap37.73052wk Low--Dividend TTM122.18MShs Float66.000Historical High--Div YieldTTM3.03%Amplitude1.410Historical Low62.089Avg Price1Lot Size
About Halozyme Therapeutics Company
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Company Profile
SymbolHALO
Company NameHalozyme Therapeutics
Listing DateNov 1, 2004
Founded1998
CEODr. Helen I. Torley, M.R.C.P.,MB.Ch.B.
MarketNASDAQ
Employees350
Fiscal Year Ends12-31
Address12390 El Camino Real
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130
Phone1-858-794-8889
Websitehttp://www.halozyme.com
Company Executives
- Name
- Position
- Salary
- Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B.
- Director, President and Chief Executive Officer
- 12.74M
- Nicole LaBrosse
- Senior Vice President, Chief Financial Officer and Principal Accounting Officer
- 4.22M
- Mark Snyder
- Senior Vice President, General Counsel, Chief Compliance Officer and Secretary
- 8.67M
- Jeffrey W. Henderson
- Chairman of the Board
- 544.82K
- Connie L. Matsui
- Independent Director
- 460.04K
- Moni Miyashita
- Independent Director
- 455.04K
- Bernadette M. Connaughton
- Independent Director
- 470.04K
- Barbara G. Duncan
- Independent Director
- 485.26K
- Matthew L. Posard
- Independent Director
- 455.04K
- Dr. Mahesh Krishnan, M.B.A.
- Independent Director
- 437.51K
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
